Pfizer (PFE) Stock Forecast & Price Target

Pfizer is benefiting from stronger 3Q 2026 results and raised FY 2026 guidance, with revenue now expected at $62.0-64.0Bn and adjusted EPS at $2.95-3.05, while estimates of $63.6-63.9Bn in revenue and $3.02-$3.16 in EPS signal execution near the top of that range. Its core franchise remains resilient as Vyndamax, Eliquis, and Nurtec outperformed, and international exposure, including emerging markets, adds diversification even as Prevnar and Comirnaty face mixed demand. The outlook is further supported by a pipeline that could drive growth through late-stage readouts in obesity and prostate cancer, plus a return to growth by the end of the decade as R&D and commercial execution mature.

Pfizer is facing a negative outlook because its base business is vulnerable to weaker commercial execution on key products like Padcev, Comirnaty, Paxlovid, and Prevnar, while 2026 guidance already reflects an expected year-over-year revenue headwind of about $1.1 billion from loss of exclusivity. The company also faces margin pressure if operating costs rise faster than revenue, and its large exposure to international markets, which account for 40% of sales, adds sensitivity to emerging-market demand and global policy shifts. On top of that, clinical or regulatory setbacks in pipeline assets, combined with drug pricing reform and tariff concerns, could slow EPS growth, compress valuation, and weigh on investor sentiment.